← Back to patent-cliff list
Anvumetostat
Tier C — Watch / tradeAnvumetostat
Amgen
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PRMT5
Indications (approved)：Non-small cell lung cancer, Solid tumour, 胰腺导管癌, 胸部肿瘤, Biliary tract cancer, 胃肠道癌症, Pancreatic cancer
Regional status
US
Phase II
2022-02-01
EU
Phase II
2022-02-01
China
Phase II
2022-02-01
Japan
Phase II
2022-02-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Anvumetostat?
Approved indications include: Non-small cell lung cancer, Solid tumour, 胰腺导管癌, 胸部肿瘤, Biliary tract cancer, 胃肠道癌症, Pancreatic cancer.
When does the Anvumetostat patent expire?
No public expiry year is available for Anvumetostat yet; this page updates once verified.
How do I get a quote for Anvumetostat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05